Smart-Money SignalNeutral · 52/100— Insiders are net sellers over 90 days (-$640K, 7 sales vs 1 buy)
Revenue$0
Net Income-$30.9M
EPS$-1.39
Market Cap$624.6M
Price Performance
Historical data including institutional events
Company Profile
R
Rachel McMinn
CEO & Executive Director
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.
The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University.
The company was founded in 2018 and is headquartered in New York, New York.
